Analyst Ratings For NASDAQ:KPTI – Karyopharm Therapeutics (NASDAQ:KPTI)
Today, JPMorgan Chase raised its price target on NASDAQ:KPTI – Karyopharm Therapeutics (NASDAQ:KPTI) to $20.00 per share.
Some recent analyst ratings include
- 4/2/2018-Leerink Swann Reiterated Rating of Outperform .
- 3/2/2018-Royal Bank of Canada Reiterated Rating of Buy.
Recent Insider Trading Activity For NASDAQ:KPTI – Karyopharm Therapeutics (NASDAQ:KPTI)
NASDAQ:KPTI – Karyopharm Therapeutics (NASDAQ:KPTI) has insider ownership of 14.71% and institutional ownership of 62.45%.
- On 3/19/2018 Michael Kauffman, CEO, sold 10,000 with an average share price of $15.29 per share and the total transaction amounting to $152,900.00.
- On 3/12/2018 Mansoor Raza Mirza, Director, sold 2,500 with an average share price of $17.01 per share and the total transaction amounting to $42,525.00.
- On 3/7/2018 Sharon Shacham, Insider, sold 10,000 with an average share price of $16.15 per share and the total transaction amounting to $161,500.00.
- On 3/5/2018 Christopher Brett Primiano, EVP, sold 2,500 with an average share price of $16.03 per share and the total transaction amounting to $40,075.00.
- On 2/20/2018 Michael Kauffman, CEO, sold 10,000 with an average share price of $14.79 per share and the total transaction amounting to $147,900.00.
- On 2/16/2018 Christopher Brett Primiano, EVP, sold 2,500 with an average share price of $15.01 per share and the total transaction amounting to $37,525.00.
- On 2/7/2018 Christopher Brett Primiano, EVP, sold 1,500 with an average share price of $13.00 per share and the total transaction amounting to $19,500.00.
Recent Trading Activity for NASDAQ:KPTI – Karyopharm Therapeutics (NASDAQ:KPTI)
Shares of NASDAQ:KPTI – Karyopharm Therapeutics closed the previous trading session at 12.60 up +0.60 5.00% with shares trading hands.